Loader

Please wait...

Canadian Pharmacists Association
Canadian Pharmacists Association
Share
Facebook Share
Twitter Share
LinkedIn Share
Google Plus Share
Email Share

Pharmacy’s future: How the COVID-19 pandemic is changing public behaviour and what that means for pharmacy

Missed the live stream? Check out the recordings! All of our Virtually Together webinar recordings, slide decks and supplementary materials are available below.

Some sessions in this series have been generously supported by unrestricted educational grants.

Watch the Pharmacy Future Recording Sept 28
Watch the Pharmacy Future Recording Sept 28
Watch the Pharmacy Future Recording Sept 28
Watch the Pharmacy Future Recording Sept 28
Watch the New Horizon Recording Dec 3
Watch the New Pandemic Response Dec 17

Pharmacy’s pandemic response: Reflections on future pandemic planning

For this session you can:

Panellists
Justin Bates, Chief Executive Officer, Ontario Pharmacists Association (OPA)
Jean Bourcier, B. Pharm., MBA Executive Vice-President and General Manager Association québécoise des pharmaciens propriétaires (AQPP)
Mina Tadrous, PharmD PhD Women's College Hospital and University of Toronto
Joelle Walker Vice President, Public Affairs, Canadian Pharmacists Association (CPhA)
Karen Sullivan Senior Director, Pharmacy Professional Affairs, Western Canada Shoppers Drug Mart/Loblaw
Annette Robinson, BSc (Pharm), CDE, CPT Regional Pharmacy Manager, Pharmasave West

Pharmacists are Canadians’ most accessible health care providers. This fact has never been more evident than during the COVID-19 pandemic. Community pharmacies remained open and pharmacists continued to provide essential medication management care to patients while other health care providers closed their doors. However, the pandemic has presented community pharmacy with many practice challenges, including procurement of PPE, maintaining continuity of care for patients, managing drug shortages and providing care to a surge of patients seeking help, all while maintaining increased infection control measures. It is essential to incorporate early lessons learned from the COVID-19 pandemic to help pharmacists be better prepared for any future pandemic or wave. This presentation will highlight key strategies and considerations in achieving patient continuity of care, safeguarding medication supply and optimizing workflow to protect staff and patients. While it is impossible to prevent a pandemic from occurring, there is much pharmacists can do to prepare.

Learning Objectives:

  1. Identify the various roles pharmacists play during a pandemic
  2. Discuss changes to workflow and practice to protect pharmacy team members and patients
  3. List challenges to continuity of care and describe solutions to overcoming these barriers
  4. Identify strategies for preparedness for future pandemics

 


New horizons for pharmacists as public health stewards

For this session you can:

Panellists
Matt Tachuk, BScPharm, RPh, Director of Pharmacy Practice, Alberta Pharmacists’ Association (RxA)
Angeline Ng, R.Ph., Director, Professional Affairs, Ontario Pharmacists Association
Jeff Mehltretter, Vice President, Pharmacy and Business Development for Neighbourhood Pharmacy Association of Canada
Carlene Oleksyn, BSP, RPh, CDE, CTH, Pharmacy Owner/Manager, Mint Health + Drugs and Consultant, colekPharm
Kerry Robinson, Executive Director, Intergovernmental, Indigenous & Stakeholder Policy Division, Public Health Agency of Canada

The COVID-19 pandemic has provided a unique opportunity for Canadian pharmacists to contribute to preventative and public health and has helped lay the groundwork for a broader role for pharmacists as public health stewards. This session will highlight how pharmacists are building on their skills and capacity as immunizers and public health educators to provide COVID-19 testing and vaccine administration, both in Canada and globally. In addition, we'll touch on other ways pharmacists can support public health, such as combating the opioid crisis through harm reduction efforts, and we'll explore barriers and facilitators to helping community pharmacists prepare for new horizons in public health.

Learning Objectives:

  1. Describe 3 key activities pharmacists could take on in a broader public health role
  2. Identify barriers and facilitators to achieving a broader public health role
  3. Explain the steps pharmacists need to take to prepare themselves for a broader public health role

Supported by an unrestricted educational grant from AbbVie


Discrimination and racism in the pharmacy profession part 2: Reflections from the pharmacy sector

For this session you can:

Panellists
Zubin Austin, BScPhm MBA MISc PhD FCAHS, Professor and Murray Koffler Chair in Management, University of Toronto
Sandra Leal, PharmD, MPH, CDCES, FAPhA, Executive Vice President, SinfoniaRx and President-elect, APhA
Justin J. Bates, Chief Executive Officer, Ontario Pharmacists Association
Jaris Swidrovich, BSP, PharmD, PhD(c), Assistant Professor, University of Saskatchewan, CSHP
Ashesh Desai, Executive Vice President, Pharmacy and Healthcare, Shoppers Drug Mart
Veronica Sison, HonBSc, PharmD Candidate, University of Waterloo

Systemic racism and discrimination are ingrained in all aspects of society, including health care, and need to be addressed in order to achieve meaningful change. The profession of pharmacy is no exception, and failure to confront explicit and implicit bias in our profession has implications for us as health care professionals and for the patients we serve. In this session, CPhA will share the results of a recent survey exploring how discrimination and racism has impacted the pharmacy profession. A panel of pharmacy leaders from academic, regulatory, association, corporate/organization and hospital sectors of the pharmacy world will follow to examine the issues raised by the profession and to reflect on potential strategies to combat racism, touching on pharmacy curricula, research and knowledge translation, policy and practice.

Learning Objectives:

  1. Identify racism and race-based discrimination in the profession
  2. Describe the impacts of racism or race-based discrimination on professional practice
  3. Describe potential strategies to combat racism and race-based discrimination within the broader pharmacy sector (e.g., curricula, research, policy and practice)

Pharmacists as opioid stewards: A showcase of the evidence

 

For this session you can:

LEARNING OBJECTIVES:

  1. List the benefits to patients and the health care system of an expanded and harmonized pharmacist opioid stewardship role.
  2. Describe opportunities where pharmacist can expand their opioid-related patient care activities by leveraging changes to scope and services
  3. Reflect on how evidence supporting opioid stewardship can be implemented in your own practice

Pharmacists have a key role to play as opioid stewards across Canada. The Opioid Evidence Showcase will feature up to 6 mini-sessions highlighting cutting-edge research that demonstrates the value of pharmacist services in opioid stewardship to both patients and the health system. Each 15-minute presentation will be followed by an interactive Q&A with the researchers. The research presented at this session supports CPhA’ s Pharmacists Opioid Stewardship Initiative (POSI), which has a long-term vision of enhancing pharmacy's ability to meet patient and health system needs by enabling harmonized scope of practice in opioid medication management. Planned sessions include a presentation of the newly published naloxone guidelines, an exploration of patient outcomes resulting from pharmacist interventions in opioid management and a timely qualitative analysis of the impacts of pharmacists’ opioid prescribing activities enabled by the current CDSA exemptions.

View individual research presentations below:

  1. What role can pharmacists have in Opioid Stewardship? Findings from a comprehensive scoping review on opioid stewardship interventions by pharmacists(Nyasha Gondora, PhD, and Feng Chang, RPh, BScPhm, PharmD, University of Waterloo)
  2. Pharmacists’ perceptions of the Canadian opioid regulatory exemptions on patient care and opioid stewardship(Lisa Bishop, BScPharm, ACPR, Pharm D, FCSHP, Memorial University of Newfoundland)
  3. An Intervention to Empower Community Pharmacists to Implement Opioid Stewardship in Acute Pain(Lesley Graham, RPh, BScPharm (Hons), MSc, University of Toronto)
  4. A review of the BCPhA Opioid Agonist Treatment training program: The evaluation and impact on community pharmacists and target patient population(Ann Johnston, MPharm, RPh, Manager, Pharmacy Practice Support, BC Pharmacy Association)
  5. New Canadian Guidelines for Naloxone Prescribing by Pharmacists(Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS, University of Alberta)

Discrimination and racism in the pharmacy profession part 1: Experiences from the front line

For this session you can:

Panellists
Shelley Morgan, PharmD, RPh, BSc CEO, Rx Billing Genie Staff Pharmacist, PharmaChoice Palermo Pharmacy
Jason Chan Remillard, BSc Zoology, BSc Pharmacy Owner/Operator, Pharmasave on Northmount
Perveen Gulati, BSc (Biol), BSc (Pharm), RPh Community Pharmacist, Shoppers Drug Mart
Kierra FineDay, BSP Community Pharmacist, Shoppers Drug Mart
Adrienne Simmons, PharmD, MS, BCPS, AAHIVP Policy Manager, National Viral Hepatitis Roundtable

Systemic racism and discrimination are ingrained in all aspects of society, including health care, and need to be addressed in order to achieve meaningful change. The profession of pharmacy is no exception, and failure to confront explicit and implicit bias in our profession has implications for us as health care professionals and for the patients we serve. CPhA is pleased to bring together a panel of pharmacists with diverse backgrounds and perspectives to begin a conversation on how discrimination and racism have impacted them, both personally and professionally. This discussion is the first of a two-part series.

Learning Objectives:

  1. Identify examples of implicit bias that you have experienced, witnessed or heard about
  2. Discuss the impact of bias and its contribution to discrimination in pharmacy practice and patient care
  3. Describe examples reflecting principles of allyship and inclusion in front line pharmacy practice
  4. Compare and contrast your own experiences with racism and discrimination to those of the panellists

Pharmacy's future: How COVID-19 is changing public behaviour and what that means for pharmacy

 

For this session you can:

Featured Speaker
David Coletto, CEO, Abacus Data
Panellists
Afomia Gebre, ACPR Candidate, Nova Scotia Health Authority
Gerry Harrington, Senior Advisor, Food, Health & Consumer Products of Canada
Kimberley Hanson, Executive Director, Federal Affairs, Diabetes Canada
Smita Patil, Senior Director, Industry Affairs, McKesson Canada

The COVID-19 pandemic has accelerated many shifts in consumer behaviour that have been happening slowly over the past few years. Throughout the pandemic, more consumers are experiencing almost entirely touchless experiences, from virtual care and home delivery of essentials like groceries, all while adapting to doing more at home. This session will explore how the pandemic may shift consumer expectations and preferences when it comes to pharmacy and their relationship with pharmacists. The anchor for the session will be a presentation by CPhA's pollster, David Coletto of Abacus Data. David will share the results of a new national survey of Canadians conducted exclusively for this event. The study will explore how perceptions and impressions of pharmacists may have changed, how consumers will want to interact with pharmacists in the future and what it could mean for the profession and sector for years to come. Following the presentation of the data, David will moderate an engaging panel of pharmacists and industry experts to explore the results on a practical, day-to-day level and what it means for the future of pharmacy.

Learning Objectives:

  1. Identify trends in consumer behaviour resulting from the COVID-19 pandemic
  2. Describe how these behavioural trends could change the patient-pharmacist relationship
  3. Summarize the potential impacts of these trends on future pharmacy practice and services